| Author | Pinho, Rosa Teixeira de | |
| Author | Waghabi, Mariana Caldas | |
| Author | Cardillo, Fabíola | |
| Author | Mengele Junior, José Orivaldo | |
| Author | Antas, Paulo Renato Zuquim | |
| Access date | 2016-12-05T19:20:38Z | |
| Available date | 2016-12-05T19:20:38Z | |
| Document date | 2016 | |
| Citation | PINHO, R. T. et al. Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable! Frontiers in Immunology, v. 7, p. 306, 2016. | pt_BR |
| ISSN | 1664-3224 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/16428 | |
| Sponsorship | CNPq-PQ-2 and FAPERJ-JCNE fellowships (PA), and fully supported by PAPES/CNPq/FIOCRUZ and Fundação Octacílio Gualberto, Faculdade de Medicina de Petropolis (FMP-FASE). | pt_BR |
| Language | eng | pt_BR |
| Publisher | Frontiers Media | pt_BR |
| Rights | open access | pt_BR |
| Subject in Portuguese | Doença de chagas | pt_BR |
| Subject in Portuguese | Biomarcadores | pt_BR |
| Subject in Portuguese | Experimentação humana | pt_BR |
| Subject in Portuguese | Testes clínicos | pt_BR |
| Title | Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable! | pt_BR |
| Type | Article | pt_BR |
| DOI | 10.3389/fimmu.2016.00306 | |
| Abstract | Biomarkers or biosignature profiles have become accessible over time in population-based studies for Chagas disease. Thus, the identification of consistent and reliable indicators of the diagnosis and prognosis of patients with heart failure might facilitate the prioritization of therapeutic management to those with the highest chance of contracting this disease. The purpose of this paper is to review the recent state and the upcoming trends in biomarkers for human Chagas disease. As an emerging concept, we propose a classification of biomarkers based on plasmatic-, phenotype-, antigenic-, genetic-, and management-related candidates. The available data revisited here reveal the lessons learned thus far and the existing challenges that still lie ahead to enable biomarkers to be employed consistently in risk evaluation for this disease. There is a strong need for biomarker validation, particularly for biomarkers that are specific to the clinical forms of Chagas disease. The current failure to achieve the eradication of the transmission of this disease has produced determination to solve this validation issue. Finally, it would be strategic to develop a wide variety of biomarkers and to test them in both preclinical and clinical trials. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Genômica Funcional e Bioinformática. Rio de Janeiro, Brasil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil / Faculdade de Medicina de Petropolis (FMP-FASE). Petrópolis, RJ, Brasil | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Clínica. Rio de Janeiro, RJ, Brasil | pt_BR |
| Subject | Chagas disease | pt_BR |
| Subject | Biomarkers for immune responsiveness | pt_BR |
| Subject | Human experimentation | pt_BR |
| Subject | Clinical forms | pt_BR |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
